Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Earnings Results, Beats Expectations By $0.21 EPS

Posted by Stanley Muller on Jul 30th, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21, FiscalAI reports. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the company earned ($0.51) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% compared to the same quarter last year.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

AMVUTTRA delivered record growth, with TTR revenue reaching $1.03 billion and total net product revenue rising 74% year over year to approximately $1.2 billion in Q2. AMVUTTRA revenue exceeded $1 billion for the first time, implying an annualized run rate above $4 billion.
Alnylam lowered 2026 TTR revenue guidance by $200 million at the midpoint to $4.2 billion-$4.5 billion, citing normalization of pent-up second-line demand after the initial launch. Total net product revenue guidance is now $4.7 billion-$5.1 billion.
Management emphasized strong long-term commercial fundamentals, including approximately 80% of new treatment starts coming from the first-line setting, more than 90% adherence, broad reimbursement access, and over 1,700 new prescribers added since the ATTR-CM launch. The company also sees potential benefit from the expected mid-2031 U.S. generic entry for tafamidis and AstraZeneca’s unsuccessful CARDIO-TTRansform study.
The company announced a collaboration with BeOne to commercialize and distribute AMVUTTRA in mainland China and Macau, subject to regulatory approval. Alnylam is also expanding AI partnerships focused on drug discovery, disease identification, and earlier ATTR-CM diagnosis.
Alnylam maintained confidence in the ongoing TRITON-CM study of nucresiran despite the competing eplontersen trial failure, citing differences in molecule characteristics, study design, and prior RNAi data. Management may adjust enrollment or the statistical analysis plan after reviewing the full competitor data, while several pipeline readouts are expected in the second half of 2026.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $81.14 on Thursday, reaching $205.48. The company’s stock had a trading volume of 9,825,785 shares, compared to its average volume of 1,361,226. The stock’s 50-day moving average is $291.70 and its two-hundred day moving average is $313.42. Alnylam Pharmaceuticals has a 52-week low of $197.81 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The stock has a market capitalization of $27.43 billion, a P/E ratio of 56.14 and a beta of 0.27.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Orbis Allan Gray Ltd increased its holdings in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after purchasing an additional 175,951 shares during the period. Northern Trust Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Northern Trust Corp now owns 857,742 shares of the biopharmaceutical company’s stock worth $341,081,000 after purchasing an additional 24,591 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $369,943,000. Finally, Charles Schwab Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 4.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 647,839 shares of the biopharmaceutical company’s stock valued at $257,613,000 after buying an additional 29,069 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Needham & Company maintained a Buy rating while lowering its price target from $510 to $357. The new target still implies substantial upside from recent trading levels, suggesting the analyst views the selloff as excessive. Benzinga analyst price target report
Positive Sentiment: Second-quarter adjusted earnings were reported at $1.84 per share, above the consensus estimate cited by the company’s earnings report, compared with a loss of $0.51 per share a year earlier. Revenue rose 66.9% year over year to $1.29 billion, highlighting strong underlying growth. Alnylam second-quarter earnings report
Positive Sentiment: Earlier coverage highlighted encouraging new Alzheimer’s RNAi data and quarterly revenue exceeding $1 billion, providing potential longer-term support from Alnylam’s pipeline. Alzheimer’s RNAi data and revenue article
Neutral Sentiment: Quarterly results were mixed relative to different analyst benchmarks: Zacks reported that EPS of $1.84 missed its $2.05 consensus estimate, while revenue of $1.29 billion came in below the $1.32 billion estimate. Zacks Alnylam earnings analysis
Negative Sentiment: Alnylam lowered its fiscal 2026 outlook, projecting revenue of $5.3 billion to $5.7 billion versus a $5.6 billion consensus estimate. Management cited normalized demand for second-line Amvuttra, raising concerns about the pace of future growth and prompting the heavy selling. Alnylam lowers 2026 outlook article

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALNY. HC Wainwright lifted their target price on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Friday, July 10th. Finally, Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $445.48.

Get Our Latest Stock Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.